Significance of Pharmacokinetics for Drug Design and the Planning of Dosage Regimens by Rossum, J.M van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/143014
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
rtepnm eu Trom:
DRUG DESIGN, V O L  1 
©  1971
A cadem ie  P r « v  Inc., N ew  York and  London
Chapter 7 Significance of Pharmacokinetics for 
Drug Design and the Planning of 
Dosage Regimens
J . M. van Rossum
I. I n t r o d u c t io n ................................................................................................... 470
II. The Biological Half-Life of D r u g s .............................................................. 470
III. Single-Compartment Kinetics: The Relationship between the Biological 
Half-Life and the Elimination Clearance and Volume o f Distribution . 474
IV. Single-Compartment Kinetics: Oral A dm in istra tion ............................... 479
V. Drug Kinetics from Urinary Excretion D a t a ............................................481
VI. Kinetics o f Drug M e ta b o l i s m .................................................................... 490
VII. Two-Compartment Kinetics: Plasma Concentration Curves following 
Intravenous Drug A d m in is tra tio n .............................................................. 495
VIII. Two-Compartment Kinetics: Plasma Concentration Curves following 
Oral Drug A d m in is t ra t io n .......................................................................... 503
IX. Plasma Concentration during Chronic M e d ic a t io n ............................... 507
X. The Average Plasma Concentration during Chronic Medication . 511
XI. The Daily Urinary Excretion in the Steady State during Chronic
M e d i c a t i o n ................................................................................................... 514
XII. Drug Availability and the Plateau Plasma Concentration after Chronic
M e d i c a t i o n ....................................................................................... 515
XIII. Nonlinear Distribution and Elimination P r o c e s s e s ............................... 516
R eferences......................................................................................................... 517
470 J. M. VAN ROSSUM
I. Introduction
The intensity of effect produced by a drug depends on the degree of receptor 
occupation, which, in turn, is determined by its affinity toward the receptors 
and the concentration of the drug in the direct environment of the receptors,
i.e., in the receptor compartment.
In man and animals the drug concentration near the receptors is governed 
by the concentration in the target tissue and also by the drug concentration in 
the blood plasma. Following oral administration of a drug in an animal or man, 
the plasma concentration increases toward a maximum and thereafter falls off 
to low levels. Different drugs show generally a different plasma curve due to 
differences in the rate of absorption, distribution, and elimination.
As biotransformation in general is an important aspect of the elimination 
process, active metabolites may possibly be formed. These metabolites may 
also contribute to the effect produced. In such a case the rate of formation and 
elimination of the active metabolites are of importance for the pharmacological 
effect of a drug. Pharmacokinetic information is therefore of great importance 
in drug design. For the major part, drug design is concentrated onimprovements 
of already existing drugs (see Volume II), which implies that in this approach 
mainly pharmacokinetic properties are being changed. Only in exceptional 
cases is drug design directed to the development of entirely new drugs through 
a rational application of the knowledge o f enzymic processes (see Chapter 1, 
this volume, and Chapters 1 and 2 of Volume II).
In animal tests often a drug is given in an acute situation as a single dose 
medication. In drug therapy, however, drugs are usually given repetitively over 
weeks or in chronic cases, over several months. It is evident that great 
differences may occur following single dose or chronic medication, not only with 
respect to the drug level, but also with respect to accumulation of metabolites. 
Optimalization with regard to dosage regimens are required for a fruitful drug 
therapy (52,53).
This review will discuss the use of pharmacokinetics in drug design and the 
optimalization of dosage regimens. Several excellent papers on pharmaco­
kinetics may be consulted from the literature (2, 3, 11, 24, 25, 29-32, 34, 39, 
71, 78,113,117,131).
II. The Biological Half-Life of Drugs
For a large number of drugs, administered intraveneously, the time course 
of the drug concentration in the blood plasma has the shape of the curves in 
Fig. 1. The plasma concentration, which is high initially, falls more or less
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Fig. 1. Serum and plasma concentration curves calculated on the basis o f single-compart- 
ment kinetics from serum or plasma data in human subjects following intravenous injection 
o f drugs, (a) Sulfathiazole IV 1000mg; patiënt, 21.6 kg; tm  -  2 hr 14 min; C0 =  142 mg/liter 
[redrawn from Dost and Gladke (55)]. (b) Indocyanine green IV 0.1 mg/kg; / I/a = 2.7 min; 
C0 = 2 mg/liter [redrawn from Cooke et al. (21)]. (c) Ethylbiscoumacetate IV 600 m g; patiënt, 
60 kg; tm  =  54 m in; C0 =  112 mg/liter [redrawn from van Dam (99)]. (d) Rolitetracycline IV 
275 mg; t U2 = 8 hr; C0 =  5.8 mg/liter [redrawn from Reubi and Münger (79)]. There is 
good agreement between the experimental data and the calculated curves; however, there 
are too few points indicated for indocyanine green.
rapidly, and progressively slower as the plasma concentration decreases. 
The plasma concentration of sulfathiazole in a certain patiënt is reduced to 50 % 
of its initial value in 54 min (55). Upon the elapse of another 54 min the plasma
T A B L E  I .  B io l o g ic a l  H a l f - L iv e s
Drug *1/2 References
Penicillin G 30-50 min Plaut et al. (74)
Cephalothin 40- min Naumann (70)
Cephaloridine 90 min Naumann (70)
Ampicillin 1 hr Reubi and Vorburger (80)
Streptomycin 2-3 hr Boxer et al. (12)
Bacitracin 77 min Eagle et al. (36)
Erythromydn 2-3 hr Walter and Heilmeyer (127)
Rifamycin 1 hr 30 min Bergamini and Fowst (8)
Kanamycin 4 hr Cutler and Orme (22)
Tetracyclitie ;r 8-10  hr Walter and Heilmeyer (127)
Oxytetracycline 9 hr 12 min Walter and Heilmeyer (127)
Chlortetracycline . 2-3 hr Brainerd et al. (13)
Rolitetracycline ' 4 -4 J h r Reubi and Münger (79)
Chloramphenicol 4 hr Weiss et al. (128)
Novobiocin 1-3 hr Wagner (115)
Lincomycin 4 i - 5 ih r Wagner (125)
Vitamin A 8 h r Dost (34)
Vitamin D 40 days Dost (34)
Vitamin Bj 20 min Dost (34)
Folie acid 40-45 min Spray and Witts (94)
Ascorbic acid 16 days Burns (17)
Inulin 30 min Polster (75)
Bromsulfalein 5 im in Wichmann (130)
Indocyanine green 2.7 min Cooke et al. (21)
Bilirubin 60 min Engstedt et al. (37)
Mandelic acid 2 hr Kamienny et al. (51)
p-Aminosalicylic acid 45 min-1 hr Walter and Heilmeyer (127)
Isonicotinic acid hydrazide 2-3 hr Walter and Heilmeyer (127)
Sulfadimidine 7 hr von Rieder (107)
Sulfathiazole - 3 hr 50 min von Rieder (107)
Sulfaphenazole 10 hr von Rieder (107)
Sulfacetamide 7 hr von Rieder (107)
Sulfadiazine 17.hr Krüger-Thiemer (53)
Sulfanilamide 9 hr Krüger-Thiemer (55)
Sulfamerazine 24 hr Krüger-Thiemer (53)
Sulfamethoxypyridazine 35 hr Krüger-Thiemer (53)
Sulfamethoxypyrazine 60 hr Krüger-Thiemer (53)
Sulfadimethoxine 41 hr Krüger-Thiemer (53)
Sulfadimethoxypyrimidine 38 hr Bünger et al. (16)
Sulfapyrimidine 17 hr Bünger et al. (16)
Tolbutamide 3 Jh r Stowers et al. (95)
Glybenclamide (HB 419) 6 hr Heptner et al. (48)
Chlorpropamide 3 4 | hr Stowers et al. (95)
Carbutamide 40 hr Stowers et al. (95)
Bromide 7} days Wilbrandt (132)
Iodide 6i  hr Wilbrandt (132)
Calcium 3 hr Dost (34)
Lead 70 days Wilbrandt (132)
Iron 1- l i h r Rommel et al. (85)
TABLEII. B io l o g i c a l  H a l f - L iv e s
Drug h /2 References
Acetosal 20 min Rowland et al. (89)
Salicylic acid 4 -4 ih r Riegelman et aL (83)
Phenacetine 45-90 min Prescott (76)
Phenazone 10-15 hr Vesell and Page (106)
Phenylbutazone 3 days Bufns et al. (18)
Hydroxyphenylbutazone 3 days Burns et al. (18)
Aminophenazone 3 hr W ilbrandt (132)
Paracetamol 95-170 min Nelson and M orioka (72)
Barbital 4-5 days W ilbrandt (132)
Phenobarbital 3 i days Ravn-Jonsen et al. (77)
Butobarbital 30-45 hr Lamers (5ua)
Pentobarbital 42 hr D ost (34)
Thiopental 16 hr Dost (34)
Hexobarbital 17 hr Siegert et al. (92)
Glutethimide 10 hr Biitikofer et al. (19)
Paraldehyde hr Thurston et al. (98)
Diphenylhydantoin 9 hr M 0 lholm-Hansen et al. (67)
Meprobamate 11-14 hr Hollister and Levy (50)
Diazepam 27-28 hr de Silva et al. (23)
Ethylbiscoumacetate 1-2  hr van Dam (99)
Dicoumarol 32 hr W ilbrandt (132)
Warfarine 30-40 hr Nagashima and Levy (69)
Heparine 60-90 min Estes et al. (38)
Digitoxine 4-6 days Lukas and Peterson (62)
Digoxine 40-50 hr Doherty et al. (27)
Xylocaine 75 min Scott et al. (90)
Pentazocine 2 hr Berkowitz et al. (10)
Norephedrine 4 hr Heimlich et al. (76)
Ephedrine 3-4 hr Wilkinson and Beckett (133)
Methylephedrine 4-5 hr Wilkinson and Beckett (133)
Methoxyphenamine 8-15 hr Vree (108)
Dexamphetamine 6-7 hr Vree and van Rossum (111)
(+)-Methamphetamine 12-14 hr Vree and van Rossum (111)
(+)-Ethylamphetamine 13-17 hr Vree and van Rossum (111)
(+)-Isopropylamphetamine 2-3 hr Vree and van Rossum (111)
(+)-Dimethylamphetamine 5^-6 hr Vree and van Rossum (111)
Phentermine 19-24 hr Vree and van Rossum (111)
Mephentermine 17-18 hr Vree and van Rossum (1.11)
Chlorphentermine 37-38 hr Vree and van Rossum (111)
Pipradrol 22-27 hr Vree and van Rossum (110)
Fencamfamin 10-12 hr Vree and van Rossum (110)
Caffeine 3 i-6 h r Grab and Reinstein (93)
Lysergide (LSD) 3 hr Aghajanian and Bing (1)
Imipramine 3±hr Wilbrandt (132)
Desipramine 30-35 hr Hammer et al. (44)
Mepacrine 5 days Wilbrandt (132)
Hexamethonium l i  hr Dost (34)
Tubocurarine 12-15 min Mahfouz (65)
Succinylcholine 3J min Levy (57)
Noscapine 40-50 min Vedsö (105)
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concentration is further reduced by a factor of 2, or to 25 % of its initial value. 
The time required to reduce a given plasma concentration to 50 % has been 
called the half-time value or biological half-life (24, 25, 34, 71, 96, 97).
For many drugs the biological half-life may be considered to be a measure 
by which the elimination process is characterized. In Tables I and II, half-lives 
are given for a number of drugs (34,132). It may be seen that the half-life of 
various drugs may differ tremendously. This is true also for drugs that belong 
to the same pharmacological class.
The duration of drug action largely depends on the dose given and its 
biological half-life. After 3.3 times the half-life 90% of the drug is eliminated, 
while only 1 % is left in the body after 6.7 times the half-life.
The biological half-life is actually only a measure for the elimination rate 
of a drug from the body under the condition that drug absorption and distribu- 
tion are fast with respect to elimination. It is therefore obvious that it is not 
useful to determine the biological half-life of a drug given as a sustained release 
or retard medication. A comparison of the biological half-life of sodium 
penicillin with procaine penicillin as may be found in the literature (132) is 
therefore misleading and confusing. If drugs are to a substantial degree bound 
to plasma proteins, the biological half-life may be found to vary with the dose 
that is administered (54-56). The biological half-life is only a true elimination 
constant when single compartment kinetics are valid and the elimination 
process is first-order.
III. Single-Compartment Kinetics: The Relationship between the Biological 
Half-Life and the Elimination Clearance and Volume of Distribution
If the elimination of a drug from the body proceeds in a manner as observed 
for sulfathiazole, elimination occurs according to a first-order process (Fig. 1). 
The higher the drug concentration in the body fluid, the more rapidly the 
elimination proceeds. The elimination rate can be described by the following 
differential equation (1):
dQ , r  nr dC k cl ,
S — k " c  or ~ g — v , c  (1 )
where dQ/dt is the elimination rate (e.g., in mg/hr), k el the elimination clearance 
constant (e.g., liters/hr), and C the drug concentration in the plasma (e.g., in 
mg/liter). Elimination of drug is considered as a clearance from a single 
compartment with a volume Vf . This does not mean that the concentration in 
the body is necessarily equal for all parts or tissues, but only that exchange of
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drug between the various tissues and the blood plasma is rapid as compared 
with the rate of elimination. The body may then be considered as a single 
compartmental reservoir with a fictive or apparent volume of distribution.
Integration of Eq. (1) leads to the well-known equation for the drug con­
centration in the plasma as a function of tim e:
C  =  C0 e-t/TeI =  C0 2- t / t l ' 2 (2)
O)
Time (m in) T im e (hr)
Fig. 2. Serum and plasma curves plotted on a semilog scale by using the data o f Fig. 1.
(a) k cl = 36.4 ml/min; Vf  =  7.0 liters, (b) k*  = 960 ml/min; V* =  3.75 liters, (c) kcl — 69 
ml/min; Vf  =  5 .4 liters.(d)fcei =  68.4ml/min; Vf  = 47.4liters.
where C0 is the initial plasma concentration, r el the elimination time constant, 
and t l/2 the half-time (f1/2 =  0.693reI).
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Fig. 3. The influence of a pathological condition on the elimination half-Iife o f drugs.
(a) Kanamycin clearance in patients with renal disease and healthy subjects. Kanamycin 
sulfatein 7 mg/kg; ( • )  patients with renal disease, k„cM = 8 ml/min, tm  = 25 hr; (o ) patients 
with normal renal function, kcrcat = 83 ml/min, t U2 =  1 hr 30 min [from Cutler and Orme (22)].
(b) Rolitetracycline in patients with severe kidney impairment and in a healthy person. 
Rolitetracycline IV 275 m g; ( • )  patients with renal diseases, kel = 0, t U2 = 30 hr; (o) patients 
with normal renal function, k,, >  100 ml/min, t in  = 8 hr [from Reubi and Münger (79)].
(c) Indocyanine green in a healthy subject and a patiënt with cirrhosis. Indocyanine green IV 
0.1 mg/kg; ( • )  cirrhotic patiënt; (o ) patiënt with normal liver function [from Cooke et al. 
(21)]. (d) Meprobamate in a patiënt with impaired liver function and in healthy persons. 
Meprobamate IV 8 mg/kg; (a )  patiënt with liver disease; (o) patiënt with normal liver func­
tion. In patients with insufficiënt renal or liver functions, the biological half-life of a drug 
is longer as compared to healthy subjects [from Held and von Oldershausen (47)].
Such first-order elimination leads to an equation with only one experimental 
term and a time constant r eI equal to the quotiënt of the volume of distribution
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TABLEH I
R e l a t i o n s h i p  b e t w e e n  E l i m i n a t i o n  C l e a r a n c e  C o n s t a n t ,  kel, t h e  V o lu m e  o f  D i s t r i b u -  
t i o n ,  Vf , E l i m i n a t i o n  T im e  C o n s t a n t ,  t c1, B i o l o g i c a l  H a l f - L i f e ,  i ll2, a n d  E l im in a ­
t i o n  C o n s t a n t ,  rtl (W h e n  t h e  H u m a n  B o d y  I s  R e o a r d e d  a s  a  S in g l e - C o m p a r t m e n t a l
R e se r v o ir )
Elimination process
v f
(liters) h l2 rc i
Clearance equal to 
glomerular filtrat ion from 
a volume equal to the 
extracellular fluid
130 ml/min 
7.8 liters/hr
12 1 hr 3 min 1 hr32m in 0 .011/min 
0.65/hr
Clearance equal to  urine 0.7 ml/min 36 576 hr 864 hr 0 .0012/hr
flow from a  volume equal 
to  the total body water
42.0ml/hr
l.Oliters/day
25 days 36 days 0.040/day
Clearance equal to  renal 
plasma flow from a 
volume equal to total body 
water
700.0 ml/min
42.0 liters/hr
36 35 min 51 min 0.096/min
1.17/hr
Clearance equal to  liver 
plasma flow from a 
volume equal to  the plasma 
volume
1.0 liters/min
60.0 liters/hr
3 2 min 3 min 0.33/min
20 .0 /hr
Slow clearance from a large 2 ml/min 360 2000 hr 3000 hr 0.00033/hr
fictive volume 120ml/hr 89 days 128 days 0.0070/day
Fast clearance from a very 120 ml/min 1440 138 hr 200 hr 0.0050/hr
large fictive volume 7.2 liters/hr 5.8 days 8.3 days 0 .12/day
and the clearance constant ( re, =  Vf /k el). The reciprocal of the time constant 
r el is the elimination rate constant rel (where 'el =  I/Tel)-*
From Eq. (2) it follows that the logarithm of the drug concentration in the 
plasma decreases linearly with time.
logC  =  logC0 -0 .3 0 1 (//f1/2) (3)
A semilogarithmic plot of the data of Fig. 1 reveals straight lines as required 
for single-compartment fïrst-order kinetics (see Fig. 2). The volume of distribu- 
tion may be obtained from the quotiënt of intercept of the semilogarithmic
* In many papers on pharmacokinetics (52, 53, 71, 113) the rate constant is denoted with 
the symbol k, and is used in the differential equation:
dC/dt = - k el C or dQjdt =  -k . ,  Q
This kel is the elimination rate constant for which in this paper the notation re, is used. In 
order to prevent confusion with the literature in which the notation k is used for the rate 
constants whereas in this paper the notation k  is used for the clearance constants we prefer 
to use the notation r for the rate constant r =  k.
478 J. M. VAN ROSSUM
concentration-time curve and the doseadm inistered(Ff =  C0/D). Once Vf  and 
r el, rel or t l/2 have been calculated, the elimination clearance constant can be 
determined.
*.i =  Vf /rcl = Vf rcl =  1.44 Vf / tm  (4)
A large r el or long half-life does not necessarily imply a slow elimination 
process. A drug that is rapidly cleared may still reveal a large t 1/2 when the 
volume of distribution is very large. The elimination clearance and therefore 
the t1/2 varies with the condition of the patiënt. In the case of renal insufficiency 
or liver disease, the biological half-life is in general increased (see Fig. 3). The 
relationship between the half-life and rate constant and the volume of distribu­
tion and the clearance constant for a number of theoretical cases is given in 
Table III.
Under the assumption of single-compartment first-order kinetics, the 
clearance constant is calculated from the biological half-life and the volume 
of distribution for a number of drugs (see Table IV).
From data of Tables III and IV, it may be evident that one may not conclude
TABLEIV
E l i m i n a t i o n  C l e a r a n c e s ,  k cU t h e  E l i m i n a t i o n  T im e C o n s t a n t ,  t cU t h e  E l i m i n a t i o n  
H a l f - L i f e ,  t V i ,  t h e  E l i m i n a t i o n  R a t e  C o n s t a n t ,  r el, a n d  t h e  F i c t i v e  V o lu m e  o f  
D i s t r i b u t i o n  o f  C e r t a i n  D r u g s  C a l c u l a t e d  f r o m  P la s m a  C u r v e s  u n d e r  t h e  
A s s u m p tio n  T h a t  t h e  S i n g l e - C o m p a r tm e n t  K in e t i c s  A r e  V a l i d
Drug v , w
k e i 
(ml/min)
T«1
(hr)
rt ï 
(hr) *1/2 References
Indocyanine green 3.75 960 0.065 15.4 2.7 min Cooke et al. (21)
Sulfathiazole 7.0 36.4 3.2 0.31 2 h rl4 m in Dost and
Penicillin G 21 420 0.84 1 35 min
Gladtke (35) 
Plaut et al. (74)
Rolitetracycline 47 68 11.5 0.087 8 hr Reubi and
Kanamycine 5.4 69 1.29 0.77 54 min
Münger (79) 
Cutlerand
Ethylbiscoum- 47.4 68 11.5 0.087 8 hr
Orme (22) 
van Dam (99)
acetate
Digitoxine 37 4.1 149 0.00067 4.3days Lukas and
Meprobamate 54 43 21 0.047 15hr
Peterson (62) 
Held and von
Dexamphetamine 250 255 17.3 0.058 12hr
Oldershausen
(47)
Rowland (86)
Xylocaine 100 700 2.4 0.44 1 hr40m in Scott et al. (90)
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from biological half-lives alone that a drug is metabolically stable or not. 
Elimination clearance constants are a better measure than half-life values.
It must be noted here that the supposition that the body may be considered 
as a single compartment is too simple (82, 122). The elimination clearance 
constant can nevertheless be calculated from plasma curves in the case of 
multicompartment kinetics. In that case the semilogarithmic plasma curves 
are not linear. Deviations from linearity in the semilogarithmic plasma curves 
may also be caused by higher order processes as in the case of binding of drug 
to plasma proteins or to other tissue components (54,55).
It must be emphasized here that most of the t m  values presented in Tables 
I and II are based on insufficiënt data, as linearity of the semilogarithmic 
concentration-time curves has been calculated from an insufficiënt number of 
points over a narrow time interval and/or narrow concentration interval. 
These data should therefore be considered with some suspicion.
IV. Single-Compartment Kinetics: Oral Administration
Although in drug evaluation studies in animals most drugs are given by 
the IV route, in therapeutics most drugs are given orally. The plasma curve 
then first increases toward a maximum value and thereafter decreases to Ievels 
beyond detection (see Fig. 4).
If  absorption and elimination are both first-order processes, the plasma 
concentration may be described by the foliowing equation:
where r a and r el are the constants for absorption and elimination and F is  the 
fraction of drug that becomes absorbed. F  may be taken as a measure for the 
biological availability and is dependent on how a pharmacon has been com- 
pounded to a drug product. Theoretical curves are given in Fig. 5.
If  absorption proceeds more rapidly than elimination, the descending part 
of the semilogarithmic plasma curve is linear. From this straight line the time 
constant rel can be determined (34, 71, 114).
The time constant for absorption may be obtained with a subtraction method 
provided that enough points in the ascending part of the curve are given (see 
Fig. 4). A worthwhile paper on this subject has been written by Loo and 
Riegelman (60), and several aspects of drug absorption have been reviewed 
recently (26, 118, 121, 123).
The biological availability, F, ultimately may be calculated from the area 
under the plasma curve. It is evident that the total quantity of drug eliminated, 
Qei, can be obtained by integration of dQeJdt as shown in Eq. (6).
(5)
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Time (min) Time ( hr)
Time (hr)
Fig. 4. Plasma or serum concentration curves calculated on basis of single-compartment 
kinetics from plasma or serum data in human subjects following oral administration of drugs,
(a) Acetylsalicylic acid (open points). ?1/2 =  19.5 min. The line through the solid points 
represents the absorption phase. [From Rowland et al. (59).] (b) Tetracycline (open points). 
*i/2 =  5 hr 24 min. The line through the solid points represents the absorption phase. [From 
Wagner (115).] (c) Butobarbital, 200 mg. ( • )  Subject k;  rI/2 = 41 hr. (o) Subject D; 
*i/2 =  36 hr. [From Lamers (56a).]
e, 00- J rföedt = k. j c d , DF (6)
This implies that D F  can be calculated from the so-called area under the 
curve, provided that kel has been determined. Thereafter Vf  can be calculated
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from the intercept (C0) with the ordinate of the straight descending part of the 
semilogarithmic plasma curve.
Vf =  DFTcJC0(rel — r a) (7)
If  absorption is complete and fast with respect to elimination, the absorption 
process may be neglected, and the situation for oral administration approaches 
the intraveneous situation. If  drug absorption is incomplete and F  =  1 a too 
small distribution volume is calculated. If  on the other hand r a/ r sl is neglected, 
while being larger than 0.1, Vf  is found too large by more than 10%.
It should be realized that following administration of a single oral dose kel 
and F  can not be evaluated in absolute values. If  the drug is also given to the 
same subject by the intravenous or intramuscular route, obviously k el and 
thus also the .F of the oral dose can be estimated.
Similarly, incorrect clearance constants will be calculated if the errors have 
been made in the evaluation of Vf  since kel is the quotiënt of Vf  and r el.
The plasma curve following an oral dose may not be described by the simple 
Eqs. (5) and (6), if the time constant for absorption equals the time constant 
for elimination. In  this special case Eq. (8) holds:
C = (D F /V f )(t/rel)e - t^  (8)
It must be stressed again that the elimination clearance constant is the best 
parameter characterizing the elimination process. It must be emphasized here 
also that if the body is not considered a single compartment, the time constant 
t c1 is not a pure elimination time constant. An erroneous estimation of k tl, 
therefore, may be done if insufficiënt plasma data are presented. If, for instance, 
the straight line of the descending part of the plasma curve bends off revealing 
a second flatter straight line, an error may be made in the estimatoin of r el as 
well as in the biological availability F. There is ample evidence that single- 
compartment kinetics is a simplistic approach (82). The biological half-lives 
collected in Tables I and II must therefore be considered with certain suspicion 
as most values given are based on insufficiënt plasma data, so that it is not 
certain if single-compartment kinetics are valid. Under these conditions of 
insufficiënt data also the volume of distribution may be miscalculated.
V. Drug Kinetics from Urinary Excretion Data
The analysis of plasma concentration curves pro vides a reasonable indication 
of the kinetic processes that occur in the body following administration of a 
drug, if indeed the plasma levels can be measured accurately. For many of the 
potent drugs, especially those that have a large volume of distribution, the
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plasma concentration is very low, even at the peak level. For certain drugs, 
depending on the sensitivity and selectivity of the analytic procedure employed, 
plasma levels cannot be determined with sufficiënt accuracy. This is true for
Time (hr) Time (hr)
Time (hr) Time (hr)
Fig. 5. Theoretical plasma concentration and renal excretion curves for oral administration 
calculated on the basis of single-compartment kinetics. (a) Plasma curve plotted on a semi- 
logarithmic scale. (b) Renal excretion rate (heavy line) and average renal excretion rate over
3 hr period (i.e., urine is collected over 3 hr intervals) both plotted on a semilogarithmic 
scale. The descending part of the plasma curve and the renal excretion rate curve are parallel,
(c) The cumulative renal excretion curve, (d) The renal excretion deficit or the amount not 
yet excreted plotted on a semilogarithmic scale. This curve is parallel with the plasma curve.
many steroids as, for instance, the active principles of contraceptive pills, and 
also potent amphetamines and Catapresan.
Several drugs are subject to renal excretion. Depending on the physical 
properties, such as hydrophilicity, lipid solubility, and pKa, a substantial renal 
clearance may be encountered. The rate of renal elimination rate is directly
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proportional to the plasma-water concentration and, in the absence of protein 
binding, to the plasma concentration, provided that the urine pH is constant 
and possible tubular secretion is concentration-independent.
(9)
T im e  (hr) T im e  (hr)
Fig. 6. Blood concentration and renal excretion deficit in a human subject following 
ingestion of 10 mg dexamphetamine sulfate. The descending parts of both curves are parallel 
suggesting single-compartment kinetics. [Data from Rowland (85).]
where dQJdt is the renal excretion rate (e.g., in mg/hr) and k r the renal clearance 
constant (e.g., in liters/hr or ml/min). From this equation it is evident that the 
renal excretion rate curve has the same shape as the plasma concentration 
curve (see Fig. 5a and b). The biological half-life, therefore, can well be evalu- 
ated from the renal excretion rate curve. See Figs. 5b, 6 , and 7. However, the 
distribution volume cannot be assessed, as k t may not be determined from 
urinary data alone.
Experimentally the renal excretion rate is not determined over infinite small 
time intervals, but over discrete periods of time as, for example, 1 or 3 hr. This
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Cumulative renal
Renal excretion excretion Renal excretion Cumulative renal
(un its /h r x 1000; (units x 1000) (m g /h r ;  log scale) excretion (mg)
Hours Hours
Fig. 7. Average renal excretion rate and cumulative renal excretion of penicillin and 
tetracycline following oral and rectal administration. Since the renal excretion rate is directly 
proportional to the plasma concentration from thé renal excretion data, it may be concluded 
that oral administration of these two antibiotics is ineffective in nonfasting subjects, and the 
rectal rate is also of limited use. [Adapted from Wagner {120).]
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implies that experimentally the average renal excretion rate is determined. 
In Fig. 5b average excretion rates over constant time intervals are given.
It is evident that unless very small time intervals are used for the collection 
of urine samples, the time constant for absorption can hardly be determined 
from such excretion rate curves.
The total amount excreted after a certain period following administration 
of a drug may be obtained by integration of Eq. (9):
where Qt is the quantity of drug excreted by the kidneys during the period t, 
while the right-hand side of the equation gives the result of the integration when 
a drug is given orally and the absorption and elimination are first-order 
processes.
In Fig. 5c, a theoretical curve is given, while in Fig. 8 experimental curves 
are given for phentermine and chlorphentermine. It is evident from Eq. (10) 
that after sufficiënt time the amount of drug excreted is unchanged in the urine 
as a fraction of the total amount of drug being absorbed. Since it is not certain 
whether following oral (rectal, etc.) administration the drug is absorbed com- 
pletely (F = 1) the total amount excreted in the urine as a fraction of the dose 
given is equal to F (k jk ei).
By using the same human subjects under the same experimental conditions 
the biological availability F  can be assessed directly from cumulative renal 
excretion data. The total quantity eliminated after sufficiënt time (t > tu2) is 
given by the following equation:
This equation is valid irrespective of the complexity of the kinetic models 
involved. Since in most biopharmaceutical studies the dose is kept constant 
and k T and k tl are parameters of drug and the subject, F  is the only variable. 
This means that QT(t =  °c) is a direct measure for the biological availability. 
Figure 7 is an example based on data from Wagner et al. (120). From this figure 
it may be concluded that the biological availability of oral penicillin in fasting 
subjects is about five times that in nonfasting, while rectal administration in 
the formulation used is still less efficient. A similar situation holds for tetra­
cycline, although the differences are less pregnant.
From Eq. (10) it follows that the logarithm of the renal excretion deficit is 
a linear function of time provided that single 'om partment kinetics is valid and 
absorption is fast as compared to elimination.
ör(* =  °o) =  DF(kljkel) G D
log [Ê?r(t=») -  ör(f)] =  log £?r(r> ~  0.301 (t/tu2) (12)
Urine (m l/m in) Cumulative renal excretion (mg base) Urine (ml/min) Cumulative renal excretion (mgbase)
<Hour>
(o)
<Hour>
(b)
Fig. 8. Average renal excretion rate curves and cumulative renal excretion of (a) phentermine and (b) chlorphentermine in the same 
human subject. Upper row: urine production rate. Middle row: urine pH  and cumulative renal excretion. Lower row: renal excretion 
rate per urine fraction. Phentermine is mainly excreted in the unchanged form in a period o f 4 days. Chlorphentermine is more lipo- 
philic and at least as stable as phentermine so that excretion proceeds very slowly. Substantial amounts are still present in the body
1 week after a single oral dose. Severe accumulation is to  be expected when chlorphentermine is t f ven daily. [After Vree (J08),]
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In Fig. 5d theoretical curves of the renal excretion deficit (the amount that is 
not yet excreted) is given. The slope of this curve is identical with the plasma 
curve and the curve for the renal excretion rate (see Fig. 5). In Fig. 6  a plasma 
curve and the curve of the renal excretion deficit has been presented (86). 
There is an excellent correlation between the plasma data and the renal 
excretion data. The latter curve is given over more than 5 half-life times, 
suggesting that indeed single-compartment kinetics are valid for dexamphet- 
amine in man. The excretion of jV-substituted amphetamines is, however, 
more complex {111). In the latter cases at least a two-compartment system has 
to be considered.
The fraction o f the dose of a drug that is excreted in the urine depends on the 
renal clearance in relation to the total clearance,
k el = k T + k m + k  o (13)
where k m is the metabolic clearance and k 0 the clearance constant for elimina­
tion via other routes.
If  a drug is mainly excreted in the urine unchanged, this does not necessarily 
imply that k t > km. For instance, norephedrine is excreted largely unchanged 
with the urine. The same holds for phentermine and chlorphentermine (see 
Fig. 8) {104, 108). The physical properties largely determine the excretion 
kinetics (see Table V). The chloroform-water partition coefficients of the 
ephêdrines are very small as compared to those o f the amphetamines or 
phentermines. In all series the lipid solubility increases with introduction of 
larger substituents (see Table V) (109). It must be concluded from these data 
that the renal clearance of the ephedrines is large as compared to those of the 
phentermines, while it is likely that the former have a smaller distribution 
volume. The biological half-life of chlorphentermine is very large so that this 
drug is excreted in the urine for several days following intake of a small oral 
dose. Both phentermine and chlorphentermine are excreted, for the most part, 
unchanged. The long half-life of chlorphentermine may therefore be due to a 
smaller k, as well as k m and larger distribution volume as compared to phenter­
mine. Further experiments revealing plasma curves and urinary excretion 
curves are necessary for a full understanding of the kinetics of these drugs. It 
may be emphasized that physicochemical data may be extremely helpful for 
an interpretation of provisional pharmacokinetic information. As pointed out 
above the renal clearance of acidic and basic drugs is dependent on the urinary 
pH (4-7,109). A fine mathematical treatment of the kinetics of renal excretion 
has recently been given by Krüger-Thiemer (52). The renal clearance constant 
is the algebraic sum of the glomerular filtration (ke) the tubular secretion k ts, 
and the tubular reabsorption k tr.
k t = k t + k ts +  k tl (14)
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TABLEV
p K„ V a l u e s  a n d  T r u e  (T P C )  a n d  A p p a r e n t  (A P C  a t  p H  7.4) P a r t i t i o n  C o e f f i c i e n t s  
o f  a  N u m b e r  o f  A m p h e ta m in e - l ik e  D r u g s  a n d  B a r b i t u r a t e s 0
Drug p K.
% 
neutral 
at pH  7.4
A PC at 
pH  7.4
(CHC13/H 20 )
TPC
(CHC!3/H 20 ) H ept/H jO
Phenylethylamine 9.88 0.33 0.075 20.8 0.277
Dexamphetamine 9.90 0.31 0.48 146 1.88
Methamphetamine 10.11 0.19 1.11 565 5.14
Ethylamphetamine 10.23 0.15 2.67 1790 38.6
Isopropylamphetamine 10.14 0.18 8.09 4460 117
Propylamphetamine 9.98 0.26 21.2 8080 312
Benzylamphetamine 7.50 44.1 1000 2250 110
Dimethylamphetamine 9.80 0.39 11.5 2890 108
Methylethylamphetamine 9.80 0.39 19.0 4760 166
Methylisopropyl- 9.45 0.88 100 11300 200
amphetamine
Benzphetamine 6.55 87.2 1000 1400 74.8
Phentermine 10.11 0.19 1.00 514 63.2
Mephentermine 10.25 0.13 1.22 866 110
Chlorphentermine 9.60 0.62 4.00 797 17.5
Norephedrine 9.55 0.70 0.001 0.035 0.001
Ephedrine 9.60 0.62 0.015 2.42 0.001
Norpseudoephedrine 9.40 1.00 0.001 0.10 0.010
Pseudoephedrine 9.86 0.33 0.070 20.0 0.029
Methylephedrine 9.30 1.25 1.00 80.6 0.912
Phenmetrazine 8.45 8.20 15.60 191 2.15
Phendimetrazine 7.55 44.0 1000 2420 8.92
Propylhexedrine 10.74 0.043 1.11 2360 173
Fenfluramine 9.10 1.96 32.30 1640 678
4-Cl-Amphetamine 9.80 0.39 0.818 206 9.10
Fencamfamine 8.70 4.76 200 4200 110
Hexobarbital 8.19 86.1 21.2 23.0
Thiopental 7.6 61.3 99.0 164.5
Butobarbital 7.86 74.4 11.5 15.5
Pentobarbital 8.03 81.3 19.0 23.4
Aprobarbital 7.90 76.4 2.57 3.37
“ After Vree et al. (109) and Yih (134).
The tubular reabsorption predominantly occurs in the undissociated or 
neutral form. The fraction of neutral drug present at the urinary pH is 
therefore of great importance (the urinary pH may be seen as a measure 
of the pH of the tubular fluid). In Table V the fraction of neutral base and 
neutral acid is given for a number of amphetamine-like drugs (109) and
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Fencamfamine HCI 20mg
----1---- 1---- ■--- 1 ----—■— ,------ '----1---- - --- t---- - --- i----1----1—
O 12 24 36 48 60 72 84 96
Hour
Fig. 9. Influence of urinary pH on the cumulative renal excretion and renal excretion rate 
of fencamfamine in a human subject following ingestion of a 20-mg dose. Upper row : urine 
flow and sodium bicarbonate excretion. Middle row: urine pH and cumulative excretion 
showing that the total amount excreted is less than 10% of the ingested dose. Lower row: 
renal excretion rate (semilogarithmic scale). Following intake of sodium bicarbonate there 
is a strong decrease of alkaline urine, while fencamfamine excretion completely stops. 
[Reproduced after Vree and van Rossum (110) with permission of the authors and the 
European Journal o f  Pharmacology.]
barbiturates (134). The pKa of benzylamphetamine is relatively low such that 
this drug is largely in the neutral form at the physiologieal pH. Benzyl­
amphetamine is hardly at all excreted in the urine (108). For these drugs the 
urinary excretion is strongly dependent on the urinary pH  (see Fig. 9). Several 
studies have been made in which the pH dependence has been demonstrated
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{4-6). The renal excretion of fencamfamin is completely suppressed by intake 
of sodium hydrogen carbonate (110). This strong suppression raises the 
possibility that perhaps also the renal tubular secretion is pH-dependent. 
Tubular secretion of basic compounds probably occurs in the ionized form. 
By raising the urinary pH there is more drug available for tubular reabsorption 
and less for tubular secretion. A further study of these excretion aspects is 
warranted.
VI. Kinetics of Drug Metabolism
Most drugs are transformed in the body by enzymes in the liver, kidneys, or 
intestine into biologically inactive or sometimes also into active metabolites. 
The rate of drug metabolism may be characterized by a metabolic clearance 
constant k m. Metabolites may be formed fast or slowly and in consequence 
may be eliminated from the body faster or slower than the parent drug. Since 
the metabolism may occur simultaneously via different routes, only a fraction 
( / m )  of the metabolic clearance may be directed to the formation of a particular 
metabolite. This metabolite in consequence is removed from the body by a 
clearance process with an elimination clearance constant k mel.
The elimination clearance constants of parent drug and metabolite may not 
only be different but their fictive volumes of distribution may differ likewise. 
If the metabolite is less lipid-soluble but more hydrophilic than the parent 
drug its volume of distribution is likely smaller than that of the parent drug, 
resulting in relative higher blood level.
In case of first-order kinetics from a single-compartment system and IV 
administration the concentration of the parent drug may be described by Eq. 
(2 ), with the following time constant:
where k m and k T are metabolic clearance constants. It is obvious that k m is the 
sum of a number of metabolic clearance constants, representing various routes 
of biotransformation. The plasma concentration of a particular metabolite may 
be represented by the following equation:
where Vfm is the volume of distribution of the metabolite and f m is the fraction 
of drug that is metabolized into that particular metabolite, r mel the elimination 
time constant for the metabolite and f mk m/kel, the fraction of the absorbed 
dose that is ultimately converted in the particular metabolite. This fraction
(15)
(16)
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Fig. 10. Theoretical plasma concentration curves o f parent drug and one metabolite 
following IV administration. The curves have been calculated on basis of single compartment 
kinetics. (a) The metabolite is more rapidly eliminated than the parent drug so that the curves 
are parallel, (b) The metabolite is more rapidly eliminated than the parent drug but the 
volume of distribution of the metabolite is small so that relative high plasma concentrations 
are obtained. (c) The metabolite is more slowly eliminated than the parent drug so that the 
slope of the curves reflect the time-constants. (d) The metabolite is slowly eliminated but has 
a small volume of distribution so that relatively large plasma concentrations are obtained. 
(e) The metabolite is slowly eliminated while the parent drug is mainly converted into the 
particular metabolite. (f) Metabolite and drug are eliminated at the same rate. (See tcxt.)
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may be evaluated from the area under the plasma curve of the metabolite, 
provided that k m and kel are known.
Obviously r el may be larger or smaller than r mel. The elimination clearance 
constant of the metabolite is equal to the quotiënt of its volume of distribution 
and its elimination clearance constant ( rmel =  Vf J k mel).
In Fig. 10 a number of possibilities for the kinetics of drug metabolism have 
been given.
1. The biological half-life of the metabolite is smaller than the half-life of 
the parent drug. The semilogarithmic plasma curves of both drug and meta­
bolite are, however, parallel since the metabolite cannot be removed faster than 
it is produced. This situation does not necessarily imply that the metabolite is 
more rapidly eliminated. If, for instance, the volume of distribution of the 
metabolite is much smaller than the parent drug, both substances may have an 
equal total clearance but a different half-life (see Fig. 10b).
2. The biological half-life of the metabolite is larger than that of the parent 
drug. The slope of the descending part of the log plasma curves of both drug 
and metabolite reflect the half-life. The metabolite persists in the body much 
longer than the original drug. The amount in the body depends strongly on the 
total amount of metabolite produced and its volume of distribution (see Fig. 
10c, d, and e).
3. Both drug and metabolite have equal half-lives. In this case the plasma 
curve of the metabolite has a rather flat maximum and the biological half-life 
of the metabolite can only be evaluated after sufficiënt time (see Fig. lOf). 
It may be seen that from insufficiënt data too large half-life values of the 
metabolite may be obtained.
It must be emphasized again that the biological half-life alone is only a very 
rough measure for the rate of metabolism. If possible, the total clearance 
constant should be determined. This information may most easily be obtained 
from plasma curves following administration of the metabolite proper.
A few experimental data with regard to the kinetics of drug metabolism are 
given in Fig. 11. It must be realized that in most examples investigated the 
metabolites leave the body slower than the parent drug. The metabolite 
concentration of ethylbiscoumacetate is about 10 times lower than the parent 
anticoagulant (see Fig. 11a) (99). The antipyretic acetylsalicylic acid is 
rapidly eliminated, mainly by deactylation into salicylic acid. This metabolite 
is relatively slowly cleared (see Fig. 11 b) (87,89). The tranquilizer diazepam is 
converted into active metabolites demethyldiazepam and oxazepam (100). 
Diazepam in mice is relatively rapidly eliminated, whereas the active metabolites 
acquire a long-lasting brain level (see Fig. 1 ld) (100). It is evident that the 
plasma curves of total radioactivity following administration of a radioactive- 
labeled drug provide very little information on the kinetics of drug metabolism. 
Kinetics o f drug metabolism may also be obtained from urinary excretion data
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Fig. 11. Plasma concentrations (etc.) of parent drug and metabolite(s) following IV drug 
administration. (a) Ethylbiscoumacetate, 530 mg (o) and 17-hydroxy metabolite (©) in a 
patiënt. [Adapted from van Dam (99).] (b) Acetylsalicylic acid (o) and the metabolite 
salicylic acid (®) in a human subject revealing the rapid conversion. Since both drugs have 
a similar volume of distribution salicylic acid is the major metabolite. Acetosal 650 mg; 
t]f2 = 19.5 min. [Adapted from Rowland et al. {89).] (c) Acetohexamide, oral, 500 mg (o) 
and metabolite ( • ) . [Adapted from Smith et al. (9J).] (d) 14C-Diazepam and metabolites in 
the brain of mice. Diazepam is rapidly eliminated whereas the metabolites areslowly removed. 
The curve of total radioactivity provides very little information. ( o) Total 14C; (A) demethyl- 
diazepam; (®) oxazepam; (&) diazepam. [From van der Kleijn (100) reproduced with per- 
mission of the author and the Arch. Int. Pharmacodyn.]
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(see, for instance, Fig. 12) (112,121). From this figure it may be seen that there 
is a large difference in the rate o f  elimination o f  the optical isomers o f  t/-iso- 
propylamphetamine. Analysis o f these data provide evidence that the stereo- 
specific difference in the metabolism of TV-alkyl derivatives of amphetamine is
Cumulative renal Cumulative renal
Urine (m l/m in) excretion (mg base) Urine (m l/m in ) excretion (mg base)
(/j.g /m in ; log scale) 
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T i
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(/j.g /m in ; log scale) 
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0.1
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Fig. 12. Renal excretion curves of the optical isomeric forms £(+)- and /?(-)-isopropyl- 
amphetamine in the same human subject. Upper row: urine flow. Middle row: urine pH and 
cumulative renal excretion of isopropylamphetamine (closed circles) and the metabolite 
amphetamine (open circles). Lower row: average renal excretion rate for each urine fraction 
for the parent drug (dark area) and the metabolite. The dextro isomer is rapidly eliminated in 
comparison to the /-isomer. The renal excretion data suggest that S-isopropylamphetamine 
is deaminated preferentially over the /{-isomer. [Reproduced after Vree (705).]
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due to differences in the deamination, rather than to differences in the 
dealkylation pathway.
Information on the kinetics of metabolism of drugs is of great importance 
for the interpretation of structure -activity relationships in vivo. If one or more 
metabolites are biologically active it is not possible to evaluate the activity of 
a drug proper. For instance, shortly after iv injection, most of the drug is still 
unchanged but after various time intervals the drug concentration decreases 
and the metabolite concentration increases and later decreases. Since the 
biological activity of a drug in most cases is determined at a fixed time after 
administration, it is of importance at what time after injection the eifect is 
taken as a measure for the biological activity.
Also great differences may occur in the intensity of the effect as well as in the 
quality of effect, following IV, or oral administration. The effect of IV diazepam 
is probably due to diazepam itself. lts effect after oral administration is for a 
large part due to its desmethyl metabolite. The central stimulant effect of 
dextroisopropylamphetamine is probably due to the metabolite dexamphet- 
amine because of the rapid conversion. In animals treated with SKF-525A 
provide the evidence that rf-isopropylamphetamine is practically inactive. 
The /-isomer is not a stimulant in man. This may be caused by the slow conver­
sion of this isomer into active metabolites.
It must be stressed here that in structure activity relationship studies, 
especially for experimental drugs, for which hardly any data of metabolism 
are known, may easily be misinterpreted. It is not only of importance which 
metabolites are being formed, but also how fast they are formed and how fast 
they are further eliminated.
VIL Two-Compartment Kinetics: Plasma Concentration Curves following 
Intravenous Drug Administration
The human and animal body may be considered as a multicompartment 
system. All compartments are directly or indirectly in contact with the blood 
plasma. The rate of exchange of drug between plasma and the tissues depends 
on the blood flow through the tissues, the volume of the tissues, and the parti- 
tion of the drug between plasma and tissues.
The blood flow in various tissues varies with the activity of that tissue. 
For instance, the intestinal blood flow is increased after a meal, and the blood 
flow through the viscera is greater in a lyingposition than in a standingposition. 
The blood flow through the skin depends on the environmental temperature. 
In a hot environment, there is a strong blood flow through the skin but mainly 
via shunts. The vascularization certainly depends on the flow through the
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central compartment is equal to the quotiënt of the dose and the plasma con­
centration shortly after injection. It is obvious that the volume of distribution 
of the central compartment may be quite different for various drugs. For 
certain drugs as, for instance, acetylsalicylic acid, the central compartment
T im e  (h r)
Fig. 14. Plasma concentration curves calculated on basis of the two-compartment system 
from plasma data in human subjects following IV injection of drugs (open circles). The line 
through the closed circles represents the first term of the two-term exponential equation 
(t , and A,). (a) Griseofulvin, 122m gIV ; A t = 2.21 mg/liter, t ,  = 1.13 hr; A 2 =  1.08 mg/liter, 
t 2 =  29.7 hr. [From Rowland et al. (SS).] ( b )  Thiopenthal, 750 mg IV; Aj =  11.4 mg/liter, 
t j  =  56 min ;A 2 = 2.4 mg/liter, r 2 =  55 hr. [From Brodie et al. (15).]
may largely correspond to the volume of the extracellular fluid. For other 
drugs, as for instance for methamphetamine, the blood plasma together with 
the intracellular space of brain and salivary glands may be considered as a 
central compartment. In general the central compartment has no real physio- 
logical meaning but varies with the drug in question (see Table VIII). The 
other tissues may be considered as one or two additional compartments. Their 
volumes do not have physiological meaning either.
When the body has to be considered as a central compartment with one or 
two additional compartments, the semilogarithmic plasma curve is not a
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Time (hr)
Time (min)
Fig. 15. Plasma concentration curves calculated on basis o f a three-compartment model 
from plasma data in human subjects following IV drug administration. (a) Adapted from 
Berk et al. (9) with permission of the authors. (b) Adapted from Rowland et al. (89) with 
permission of the authors.
straight line, but is bi- or triphasic (see Figs. 14 and 15). The semilogarithmic 
plasma curves of thiopenthal (15), LSD (58), and griseofulvin (88) are biphasic, 
while those of bilirubin (9) and acetylsalfcylic acid are triphasic (89).
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In the case of a two-compartment model, the distribution and elimination 
processes may be described by a series of linear differential equations leading 
to  the following solution:
Ci = A t e~t/Tl + A 2 e~t/Tl (17)
C2 = B, e -,/T'+ B 2e-,/T> (18)
öei =  K M i  t,(1  -  <r‘/T0 +  A 2 t 2(1 -  e-/**)] (19)
Time (hr) Time (hr)
Fig. 16. Two-compartment open model and IV administration of 1000 mg pentobarbital 
in man. (a) Plasma data plotted on a semilogarithmic scale and from which the time constants 
and intercepts were calculated. The solid line is calculated by using Eq. (17). (b) Quantities 
of pentobarbital in the central compartment (6 i), the peripheral compartment (Ö 2) and the 
quantity eliminated (Qei), as a function of time. Due to the relatively large volume of distribu­
tion and the moderate elimination clearance, kcU after 24 hr about two-thirds of the drug is 
still in the body. [Data from Brodie et al. (75).]
where C\ is the concentration in the first or central compartment, C2 that in 
the second or peripheral compartment, and Qel the eliminated quantity (by 
metabolic, renal routes, etc.), respectively; A t, A 2, B t and B2 are the co- 
efficients and rj and r 2 are time constants which now depend on the volume of 
of the first (V x) and the second (V2) compartment as well as on all clearance 
constants k tl, k l2 and k 2\ (40, 83). The concentration in the first or second 
compartment cannot be calculated from plasma data, but the quantity of drug 
in the tissue can be assessed in all cases.
From plasma curves as given in Figs. 14 and 16, the coefficients A, and A 2 
may be obtained from intercepts, and r , and r 2 may be obtained from the 
slopes obtained by stripping of the curves or by a nonlinear regression analysis
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of a two-term exponential equation (20). The volume Vt and the total fictive 
volume of distribution Vf  as well as the elimination clearance constant Arc„ 
etc. can be calculated (see Tables VII and VIII).
For a number of drugs these pharmacokinetic parameters in man have been 
calculated (see Table VIII). Since there are two time constants (or eventually 
more) in the case of two- or multicompartment kinetics. It is customary to 
calculate the biological half-life from the largest time constant or slowest 
component in the plasma curve. Obviously now the 11/2 has no direct relevance 
to the fictive volume and the elimination clearance constant (see Table VII).
T A B L E  V I I
P h a r m a c o k in e t ic  P a r a m e t e r s  f o r  t h e  T w o -C o m p a r t m e n t  O p e n  M o d e l  
a n d  IV  A d m in is t r a t io n
Theoiy:
r i« 0 .5 P + 0 .5 (P 2 - 4 e ) ,/2 and r2 = 0 .5 P - 0.5(P2 - 4 Q ) 112
_ kt i  k 12 kn kt \k2\
i ’ = r 1 + r2 =  -  + -  + -  and Q = r i r2 = - -
T 1 =  1/^1 T2  =  1 \ r2 <1/2 =  0 . 6 9 3 r 2  T e l  =  V J k d
D  ( r2 — t c1) D  (rcl -  Ti) D k l2 t i t 2 
A \ = —  ----------— A l — — - ---------r- D2 — —B \ = ----
V \  ( t 2 -  T l )  V j  ( r 2 -  T l )  V2 V l  < T 2 -  T l )
Experimental:
A j ~t- A 2 — A t i  /4j +  T2 A 2 — A T  Vi — DjA
k ci =  D /A T rci = k 'J V ,  = Al A T  r2i =  k n IV2 = A T /t i  t 2A
r i2 =  k n / V i  =  (iri +  r 2) — (rei +  r 21)  =  A t A 2( t 2 — t i ) 2/A .A T t\  t 2
Vf  =  K,(l +  r12lr2i) = D (t] A i + t \  A 2)I(AT)z
B2 V2 =  B\ V2 =  DAi A 2( t2 -  Ti)IA.AT
In many cases biological half-lives have been estimated from semi- 
logarithmic plasma curves that have been drawn from only 3 or a limited 
number of points. It is in such cases not known whether single-compartment 
kinetics would be valid. It could be that if more points were made over a longer 
concentration traject, multicompartment kinetics would be revealed. Most 
half-life values, given in Table I and II, should therefore be used with some 
suspicion.
From data of plasma concentrations of pentobarbital, the plasma concentra­
tion curve has been calculated according to a two-compartment model (30,82). 
In addition the quantities in the two companments as well as the quantity 
eliminated have been calculated by using equations of Table VII. Other 
examples may be found in the literature (10,81).
TABLE VIII
P h a r m a c o k in e t ic  P a r a m e t e r s  o f  So m e  D r u g s  B a s e d  o n  a  T w o -C o m p a r t m e n t  O p e n  S y ste m  a n d  I n t r a v e n o u s  A d m in is t r a h o n
No. Drug
Dose
(mg) (mg/liter)
a 2
(mg/liter)
Tl
(hr)
T2
(hr)
*1/2
(hr) Ref.
1 Acetosal 650 67 33 0.072 0.336 0.232 Riegelman et al. (83)
2 Saiicylic acid 484 32 50 0.077 6.41 4.42 Riegelman et al. (83)
3 Penicillin G 100 8.40 2.30 0.160 0.74 0.54 Heatley (45)
4 Penicillin V 100 17.0 2.20 0.087 0.54 0.36 Heatley (45)
5 Spectinomycin 500 37.8 43.9 0.311 2.51 1.73 Wagner et al. (126)
6 Griseofulvin 142 1.55 1.10 1.368 13.68 9.44 Rowland et al. (88)
7 Pentobarbital 1000 7.0 7.55 0.70 60 41.4 Brodie et al. (15)
8 Thiopentha! 750 11.2 2.4 0.93 55 37.9 Brodie et al. (15)
9 Digitoxine 0.50 0.0128 0.0026 0.48 72.0 50 Okita et al. (73)
10 Lysergide 0.15 0.0041 0.0065 0.25 4.85 3.34 Aghajanian and Bing (1)
rc i r\2 r2t Tel kel k \2 Vx vt
No. (liters/hr) (liters/hr) (liters/hr) (hr) (ml/m) (ml/m) (litests) (liters)
1 6.29 4.00 6.58 0.16 681 434 6.5 10.5
2 0.25 4.91 7.98 4.0 25.0 483 5.9 9.5
3 3.5 1.69 2.4 0.29 546 263 9.3 15.9
4 7.2 3.15 2.95 0.139 623 273 5.2 10.8
5 0.67 1.03 1.91 1.49 68 105 6.1 9.4
6 0.161 0.31 0.33 6.21 150 289 56 108
7 0.032 0.66 0.75 31.2 36 760 68 130
8 0.097 0.79 0.20 10.3 87 720 54 268
9 0.079 1.65 0.36 14.9 43 895 32.5 180
10 0.33 1.35 2.53 3.0 76.8 318 14.1 21.7
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In the case of a three-comparement system from the triphasic plasma curve, 
three slopes and intercepts can be obtained from which kel and Vt can easily 
be determined, but this is more complex for the various other clearance 
constants. For details of the mathematics is referred to the literature (24, 25, 
29, 30, 33, 34, 60, 83). For a number of data from the literature on two- 
compartment kinetics of drugs, data have been collected which are presented 
in Table VIII. The distribution volumes of salicylic acid and acetylsalicylic 
acid are slightly smaller than the volume o f the extracellular fluid. Acetyl­
salicylic acid is metabolized to salicylic acid in the central compartment 
as shown by Rowland et al. (87). Vf  for pentothiobarbital is very large while 
Vf  for reserpine (63) and chloroquine (64) is extremely large, such that these 
drugs remain in the body for a long time, notwithstanding their large clearance.
It is evident that if drug kinetics could be governed by a two-compartment 
system, but that due to insufficiënt plasma concentration data a single com­
partment is assumed to be valid, the evaluation of the fictive volumes of 
distribution may be erroneous (82-84). Similarly, errors in the elimination 
clearance constants will be obtained if two-compartment kinetics erroneously 
have been treated as single-compartment kinetics. This error is negligible 
when A }r t > A 2t2 or A ,T t < A 2t2. The elimination clearance constant r el 
being equal to V,/kel has a value intermediate to r ,  and r 2.
V n i. Two-Compartment Kinetics: Plasma Concentration Curves following 
Oral Drug Administration
In medical practice most drugs are given by the oral or rectal route, although 
parenteral injections (intramuscular and subcutaneous) are often used. In all 
these conditions the drug concentration in the blood plasma is initially equal 
to zero and increases toward a maximum value as a result of drug absorption. 
Taking into account that the body in many cases has to be considered as a 
two-compartment system it is obvious that the plasma concentration curves 
of most drugs may be described by a three-term exponential function:
C, = A 0 e~,/T‘ +  A , e~,/T' +  A 2 éT,/Tj (20)
where r a is the time constant of the absorption process. The coefficients A0, 
A j and A 2 are composed of all clearance constants involved (see Table IX). 
The coëfficiënt A0 is negative and its absolute value is equal to the sum of the 
coefficients A, and A 2. The concentration in the peripheral compartment C2 
cannot be determined but the quantity (Q2) can be calculated at all times. 
The same holds for the eliminated quantity (Qci). For the experimental situa- 
tions it is clear that once the coefficients A 0, A ,, and A 2 and the time constants
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Time (hr)
Fig. 17. Serum or plasma concentration curves calculated on basis o f a two-compartment 
model from serum or plasma data in human subjects following oral administration. (a) 
Amiloride (closed circles). From the straight line A 2 and r 2 have been calculated. By a 
subtraction procedure the open points are obtained from which A t and r ,  have been obtained. 
Further subtraction reveals A 0 and r a of the absorption phase. Calculated from average 
data of Weiss et al. {129). (b) Reserpine (open circles). From the straight part A 2 and t 2 have 
been calculated whereafter by subtraction (curvc stripping) the other intercepts and time 
constants have been obtained. [Calculated from average data of Maass et al. (63).]
Reserpine C 250 fj.g oral (b )
= 2.66 -- 2 .4 0  Az -- 0.26 (/j.g /liter) 
r .  = 0.50 r, = 5.77 r ,  = 242 (hr)
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r a, r , ,  and r 2 have been determined the pharmacokinetic parameters, Arel, 
ky2i V\, and Vf  may be calculated (see Table IX). For an optimal evaluation 
use may be made of a computer program for a nonlinear regression analsyis 
of a three-compartment exponential equation (computer programs).
Figure 17 is an example of the kinetics based on a two-compartment system 
and oral administration. This figure is based on data of the average serum
TA B LEIX
P h a r m a c o k in e t ic  P a r a m e t e r s  f o r  t h e  T w o - C o m p a r t m e n t  O p e n  M o d e l  
a n d  O r a l  A d m i n i s t r a t i o n
Theory:
r, =  k J V 0 r 1 = 0 .5P  +  0.5(i>2-4e)1'2 r2 = 0.5P -  0.5(/>2 -  4 0 )1'2 
Ta =  1 /r. T] =  1/fi r2 =  l //*2 11/2 =  0 .693t2 rei =  Vilkel
A 0 = - ( A l + A 2) 5 o  =  - ( B ,  +  B 2 )  A l =  £,F(T2 _  T , , )  1
D F (tci -  T l )  1A 2 = -
V\ ( t 2 -  T l )  (1  -  T , / T l )
^ 1  ( t 2 -  t 0  (1  -  t ,/ t 2)
D F k n  t \ t 2 1 D F k i 2  t i t 2 1öi = t t -  —  7------- v —------;—~ ^2 =
^ 2  f'l (T 2 -  Tl) (1 -  t J t ,) K 2 K ,  ( t 2 -  Tl) (1 -  T,/t2)
Experimental:
^ i ( l  - t . / t i )  +  ^ 2(1 - t J t 2) =  A A o T ^  +  AxTi + A 2 t 2 =  A T
V, = DFIA k cl =  OFM 7’ reI =  = A /A T
,  ^ i ^ ï ( t , - t , ) j ( 1 - t . / t O O - t ,  - T j )
r ï i  — — A T /ti t 2 A r ^ - k u l V i — t  t 2 A ' A I
K/ =  Ki(l + rn lrn ) B0 V2 =  —(5 t K2 + B 2 V2)
DFAiA2( t 2 -  t 0 ( 1  -  t „ / t 2)  DFA, / 4 j ( t 2 — T , ) ( l  -  T, / t , )
5 iF 2  = -----------;T 7 r------ —  fi2F2=----------- T a t ------------
concentration of amiloride in five human subjects (129). It should be realized 
that the absolute values of Vu Vf , etc. may only be calculated when the 
biological availability, F, has been determined. In case of im or sc injection F 
is very likely equal to 1, while for the oral and rectal administration the 
degree of absorption has to be checked. It is preferable to use the data in a single 
subject and thereafter calculate the average of the parameters. Figure 17b 
gives an example for reserpine (63).
Other examples have been cited by Gibaldi for doxycycline (39).
Drug parameters calculated from these anH other experiments are collected 
in Table X.
T A B L E  X
PlIARMACOKINETlC PARAMETERS OF SOME D R U G S BASED ON A T w O-COMPARTMENT O P E N  SYSTEM AND O R A L ADM INISTRATION
Dose ^2 Ta Tl T2
No. Drug (mg) (mg/liter) (mg/liter) (hr) (hr) (hr) Ref.
1 Dcmcthylchlortetracycline 300 0.81 1.00 1.7 4.91 25.97 Doluisio and Dittert (28)
2 Amiloride 20 0.040 0.0164 0.98 4.18 38.5 Weiss et al. (129)
3 Reserpine 0.25 0.0024 0.00026 0.5 5.77 242 Maass et al. (63)
'cl f  21 Tel k t , k \ t V, Vt
No. (liters/hr) (liters/hr) (liters/hr) (hr) (ml/min) (ml/min) (liters) (liters)
1 0.054 0.044 0.144 18.52 186 149 205 268
2 0.063 0.10 0.099 15.9 448 740 430 875
3 0.33 0.13 0.022 3.0 55 209 102 670
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IX. Plasma Concentration during Chronic Medication
For most diseases the physician prescribes drugs for a repetitive medication 
o f 1 week or longer. In case of grand mal epilepsy, diphantoine is dosed in such 
way that the plasma concentration is kept above 10 mg/liter. Also antibiotics
2 .0
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I..5
l/> 1 .0
o>o 0 .8
0 .5
•nI
o»
£
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a
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ca>o
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0 .5
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Fig. 18. Theoretical plasma curve for drug accumulation following oral administration of 
a 20-mg dose on a fixed interval multiple dosage schedule (4 times per day). (a) In case of a 
single-compartment model the plasma decay curve following a single oral dose parallels that 
at the end of the chronic administration. (b) In  the case of a two-compartment model the 
plasma decay curve following a  single oral dose is much steeper than a't the end of the chronic 
administration. (See text.)
and synthetic chemotherapeutic agents are being given on a multiple dosage 
regiment in order to keep the plasma level above a minimal effective 
concentration.
If a drug is administered, respectively, orally or intravenously with constant 
dosage intervals (At) the plasma concentration at any time after the start of 
the therapy may be described, irrespective of the complexity of the kinetic 
models involved, by the following equation (103):
n J _  p -Jd r / T ,
-I------ I------1------1---l---------1------1------1------1------1------
2 3 4  5  6  7
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where n is the number of compartments involved. This means that n is the 
number of compartments of the body in case of IV administration, while for 
oral administration n is the sum of compartments of the body as well as the 
gastrointestinal tract. A t is the ith coëfficiënt, r , the i'th time constant, and j  
the number of doses that have been administered, while t is the time after 
administration of the j'th dose.
Two situations will be considered here:
1. The body may be considered as a single compartment. In this case Eq. (21) 
reduces to the following equation (101, 102):
D F(rcl -  r a) f l  -  e~jAt/T*1 1 -  e~jAt/r>c  _  ( tl — r ) p  — jat, fl _t/T., - * - " % ^ . ]  
Vf  r el [  1 -  e-* lu i  1 _  e-At/u  J
(22)
In Fig. 18a a theoretical example has been given, while Fig. 19 may serve as 
an experimental case. It may be seen that in this case accumulation occurs 
until a plateau level is reached. Since the elimination process is directly 
proportional to the concentration in the plasma, the rate of elimination 
increases also until it is equal to the rate of absorption. The plateau is reached 
after sufficiënt doses have been given {jAt > r el and jA t > _ra). The time 
constant for absorption in general is smaller than that for elimination so that 
jA t  may be very large as compared to ra,jA t  is very large as compared to r el.
If  the medication is stopped the falloff in plasma concentration is merely 
determined by the time constant for elimination (see Fig. 18a). This implies 
that the biological half-life may be determined after a single dose as well as 
after a multiple dose. From the experiment shown in Fig. 19 it may be seen that 
for these experiments the falloff is slower, as expected from the plasma curve 
of the first dose indicating that single-compartment kinetics are not valid for 
demethylchlortetracycline.
The drug concentration in the plateau is dependent on the dose (D), the 
biological availability (F), the dosage interval (A t) and the elimination time 
constant r ei or biological half-life (tx /2) (101,116, 124). The rate of accumula­
tion largely depends on the biological half-life. Practically the plateau is 
reached for 90% of its real value after 3.3 x / ,  /2. This may easily be derived 
from average plasma concentration curves (101). See Section X.
2. The body may be considered as a two-compartment system. In this case 
Eq. (21) reduces to the following equation:
I _  p - J d t / T .  1 _  p - j A t l T, I _  p - j A t t T i
C ,,„  =  A 0—  . , e~t/T‘ + A I ----------ï—  + A 2---------—  e~t,T>1U) U 1 _  e~At/Ts 1 |  _  e-At/T, 1 i _  e-Zlt/rj
(23)
A theoretical example is given in Fig. 18b. Accumulation is occurring in two 
phases according to the two time constants. The level of accumulation depends 
merely on the elimination clearance constant k cl. The plateau is reached when
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Fig. 19. Plasma concentration curves following chronic drug administration in human 
subjects. (a) Demethylchlortetracycline orally every 12 hr. From the postmedication curve 
the intercept A* and also A 2 as well as r 2 have been calculated. By subtraction from the curve 
following the first oral dose their A it t j ,  A 0, and r» have been obtained. From these co- 
effieients and time constants the plasma curve has been calculated. [From data o f Doluisio 
and Dittert(2S).] (b) Diazepam orally three times per day. Diazepam (open points) and the 
metabolite demethyldiazepam (closed points). [Adapted from de Silva et al. (23).] The 
plasma decay curve is flatter in the postmedication period than after a single oral dose. This is 
in accordance with two- or multicompartment kinetics.
(b )
Diazepam (tabiets) 10 mg t.i.d.
0 0 •o •  •
° o
* Demethyldiazepam (metabolite)
t
End of therapy
A t > r ,. The concentration in the plateau as well as after the plateau (being 
after the last dose once the plateau has been reached) is given by the following 
equation which may be derived from Eq. (23).
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Fig. 20. The two-compartment open model and oral administration. (a) The plasma curve 
following a single oral dose. The three intercepts and time constants are indicated. (b) The 
plasma curve after cessation of chronic medication once the plateau was reached. The inter­
cepts increase to a different degree. The intercept A* connected to the largest time constant is 
substantially larger than /12. This implies that the plasma curve is much flatter than following 
a single dose. (For a discussion see text.)
7. PHARMACOKINETICS 511
c , , , , ,  -  A .
(24)
From this equation and Figs. 18 and 20a, it may be seen that after cessation of 
medication the plasma concentration decreases at a slower rate than after 
administration of a single dose. This is also the case for the experiment with 
demethylchlortetracycline (28) (see Fig. 19a). Foliowing chronic medication 
theintercepts(coefficients)^*, A f,  and A* arelarger than theinterceptsfollow- 
ing a single dose, A 0, A u and A 2. It is obvious from Eq. (24) that if r a <s A t  the 
coëfficiënt A $ increases very little, but for r 2 s> A t  the coëfficiënt A* increases 
very much in comparison to A 2. In Fig. 20 the various coefficients are given. 
The coefficients A 0,A  lt and A 2 can be calculated from the plasma curve folio w- 
ing the last dose of the plateau. In general the ith coëfficiënt of the plasma curve 
following the last oral dose during chronic medication relates to the ith 
coëfficiënt of the plasma curve following a single oral dose according to the 
following equation:
A f  = A t[( 1 -  e~J/I/T‘)l(l -  e~ * /T‘)] (25)
Obviously A f  of the plasma curve in the postplateau phase ( jA t>  r ,)  is a 
simple relation of A ,:
A f  (Pi) =  Ajp. — e~*t,T‘) (26)
where Af( pl) is the ith intercept of the plasma curve in the postplateau period 
or falloff phase after the last dose (see Fig. 20). So from these coefficients those 
for the single dose may be evaluated and thereafter with Table IX the par­
ameters may be calculated.
It may be seen from Fig. 20 that if insufficiënt plasma data have been deter­
mined for establishing the plasma curve of the single dose a biological half-life 
could be determined which is far too small. Evaluation of the biological half- 
life following multiple dosing leads to an entirely different value. It must be 
emphasized that these biological half-lives have very limited significance, as 
they do not reflect the elimination process but are based on absorption, 
distribution, and elimination. The elimination clearance constants proper 
should preferably be evaluated (see Table IX).
X. The Average Plasma Concentration during Chronic Medication
The plasma concentration curve during chronic drug medication approaches 
a plateau value after sufficiënt intervals (see Figs. 18 and 19). Each dosage 
interval shows a minimum and a maximum concentration. Experimentally a
512 J. M. VAN ROSSUM
complete pïasma curve can be determined only in exceptional cases. This 
would require a large number of blood samples taken from the same subject.
It istherefore useful to  calculate the average plasma concentration over each 
dosage interval. If  a fixed dose D  is given IV, orally, rectally, or otherwise after 
a fixed dosage interval At, the average plasma concentration per interval may 
be described. In case o f multicompartment kinetics, the following equation 
for the y'th interval holds:
ƒ  C1U) dt = 1  J  Tt A J(  1 -  e ~ ^ ‘) (27)
o 0
where C1(j) is the average plasma concentration after the j th  dose, A t is the 
dosage interval, r , the time constant for the ith exponential term, and A, the 
ith intercept, while n is the number of compartments for IV administration and 
number of compartments together with the gastrointestinal compartments in 
case of oral administration.
The rate of accumulation is determined by the various time constants 
involved. This means that accumulation ocears in distinct phases, so that 
apparent accumulation plateaus are reached. From Fig. 21 it may be seen 
that in case of single-compartment kinetics the rate of accumulation merely 
depends on the biological half-life. From two-compartment kinetics an 
apparent plateau is reached after a period of time larger than r ,  (jA t > r j ,  
while further accumulation with a slower rate of increase occurs when 
jA t  >  r 2. From these figures and Eqs. (26) and (27) it may be seen that a 
component with a small intercept but a large time constant in the long run 
determines the accumulation plateau, but after a dosage regiment of short 
duration, the large time constants have hardly any significance.
These situations occur after chronic medication with chloroquine when 
after 2 weeks an apparent plateau is reached (64). During therapy for a year 
further accumulation occurs, while after cessation of long-term therapy a very 
long persistance of the drug in the body is encountered (very large r,). For very 
small A t intervals this equation reduces to that for infusion of a drug with a 
constant infusion rate (40, 41, 61). It is evident that following injection of a 
single bolus or after infusion over a long time interval, similar effects will be 
encountered with respect to decay of the plasma curve (41,61). After sufficiënt 
periods of time such that jA t  is large with respect to the largest time constant, 
a plateau is reached. The equation then reduces to (103):
<28>
where F  is the biological availability (fraction o f the dosage that becomes- 
absorbed) and k el the elimination clearance constant. This simple equation
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Days
Fig. 21. Average plasma concentration curves per dosage interval of 6 hr following 
chronic drug administration until a plateau level has been reaefcesL Only the first 6 days 
have been shown as well as the first 6 days after cessation of drug tfaeiapy. (a) Calculated on 
basis o f a single-compartment model for two drugs which differ in the elimination clearance 
constant, k ,t. The elimination half-life may be calculated from the postmedication curve,
(b) Calculated on basis o f a two-compartment model for two drugs with different time 
constants and elimination clearance constants, k tl. The latter parameter determines the 
plateau value, whereas the time constants determine the time required to reach the plateau.
514 J. M. VAN ROSSUM
holds irrespective of the complexity of the kinetics involved. It should be 
realized that
i
is equal to the area under the plasma curve both for the single oral dose 
(0 -*  oo) and the plateau dose (0  — A t) (103).
The plateau level depends merely on the dose (D), the biological availability 
(F), the dosage interval, and the elimination clearance constant. In the case of 
single-compartment kinetics,
Tel =  V/kel or f, i2 = 0.69 V/ktl
so that according to Wagner et al. (124):
C 1(pl)=1 .44  DFtip JV A t (29)
See also Wagner (119) and Wagner et al. (124). Once F  has been determined 
the volume of distribution can be determined from the average plateau 
concentration. This procedure is not valid in case of multicompartment 
kinetics. The elimination clearance constant can, however, be determined, 
provided that the real plateau has been reached and the biological availability, 
F, has been determined.
XI. The Daily Urinary Excretion in the Steady State during Chronic 
Medication
The urinary excretion rate (e.g., in mg/day) is directly proportional to the 
plasma conception provided that certain conditions are fulfilled (see Section V). 
This implies that the amount of drug excreted with the urine once the plateau 
plasma level has been reached is directly proportional to the average plasma 
concentration in the plateau:
Q^ 1 = D F kL ^
A t A t k ci ( ’
where A t is the dosage interval. The amount of drug excreted daily is obviously 
given by Eq. (30) if A t — 24 hr and proportionally larger or smaller if At is 
smaller or larger.
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XII. Drug Availability and the Plateau Plasma Concentration after Chronic 
Medication
The biological availability of a drug is in general considered to be the fraction 
of the dose administered that ultimately comes to ' ’ sorptiDn. There is ample 
experimental evidence in the field of biopharmaceutics, that different dosage 
forms of the same drug, such as tablets, capsules, powders, as well as different 
pharmaceutical preparations may be absorbed to a different degree (39, 
68,113).
Since the drug concentration in the plateau after chronic medication of a 
drug is directly proportional to the dose and the fraction of absorbed drug, 
irrespective of multi- or single-compartment kinetics, the biological availability 
can be evaluated from plateau plasma levels.
Preferably the biophannaceutical trials should be carried out in the same 
patients. That is, the various dosage forms and/or pharmaceutical preparations 
of a certain dosage form should be given during some time to the same subject 
by using the same dosage regimen. Since the elimination clearance constant 
may be considered constant for each patiënt, under these conditions the plateau 
level is directly proportional to the biological availability, F. Also if the dose 
is kept constant, as is usually the case, the availability can be expressed in 
terms of the plateau value of the reference medicament.
Experimentally it is only required to measure 2-4 plasma levels in the plateau 
for preparation A , then switch to  preparation B, and after some time measure 
also 2-4 plasma levels in the plateau (see Fig. 22). Although there may be quite 
some variation in the plateau values for each preparation among the different 
subjects, small differences in availability may still be evaluated as each patiënt 
is used as its own control, and the patients take the drugs regularly.
In most important therapeutic trials the medication is repetitive over 1 or 
more weeks. It is therefore relatively easy to obtain biopharmaceutical infor­
mation with relative few measurements, if one operates on the plateau con­
centration. In addition to these pragmatic advantages there is also theoretical 
advantage in that the method is independent of the complexity of the pharmaco­
kinetic models involved.
Especially if the peripheral compartments are large and shallow, a great 
number of points of the plasma curve have to be evaluated in order to make 
possible reasonable estimation of the biological availability from a plasma 
curve following administration of a single dose. It may be stressed that a too 
low biological availability may be evaluated from the plasma curve after a 
single oral dose of a medicament that is slowly absorbed by using a single dose
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study. In contrast the repetitive dose study provides the correct value of the 
biological availability from a limited number of determinations.
The amount of drug excreted daily with the urine may also be used as an 
index of the biological availability, F, provided that the trials with various 
dosage forms and/or various preparations of the same dosage form are 
carried out in the same subjects. Under this condition k el and k t may be assumed
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Fig. 22. Theoretical average plateau plasma levels of a drug following repetitive medication 
of two pharmaceutical preparations A  and B  both containing the same amount o f an identical 
active principle. As the clearance remains constant the plateau level in a particular patiënt is 
a direct measure of the biological availability, F. It must be concluded that the biological 
availability can be determined by estimation of only a few plasma levels, provided that each 
patiënt receives both preparations for sufficiently long periods o f time. Many more data are 
necessary if the two preparations are tested in randomly selected subjects.
to be constant during the entire trial, while D and A t are fixed so that only F  
may vary. This implies that the amount of drug excreted in the urine collected 
every 24 hr of a subject on medication A  or B  gives a direct measure for the 
biological availability provided that plateau plasma levels have been reached, 
and the patients take the drugs according to the fixed dosage regimen.
Xffl. NouMnear Distribution aad Elimination Processes
Plasma concentration data of most drugs may be described by two- or 
three-compartment models using first-order kinetics for the distribution and
*.l * 6.7 lite r/hr
*•1 = 10 lite r/h r
*.l = 12.5 liter/hr
* .l * 15 liter/hr
* . l s 20  liter/hr
— Prep: A ( F - 1 .00 )-*--*-----------------Prep :B (F =0.66)»—«— Prep: A —
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elimination processes. This implies that two- and three-compartment as well 
as multicompartment kinetics may be described by a set of linear differential 
equations, which can always be solved (52). If there is binding of drug to 
plasma proteins or to certain tissue components nonlinear differential equa­
tions are required, which are less easy to be solved analytically, but may be 
solved by numerical integration. A solution has been presented for the elimina- 
tion of a drug from a single compartment in which binding of drug to plasma 
proteins occurs under the assumption that protein binding may be character- 
ized by a single dissociation constant and a certain capacity of binding sides (52). 
I t must be emphasized that many drugs bind to plasma prc .cin to a substantial 
degree.
Certain drugs bind to certain tissue compartments as, for instance, estrogens 
to  protein in the uterus (42) and potent neuroleptics to certain brain areas (59). 
In the latter case the kinetic processes have been described by polynoms while 
the relationship between the plasma concentration and the concentration in 
the target tissue or possibly in the receptors is at least unclear. The future 
development of pharmacokinetics will depend to a large extent to an under- 
standing of the nonlinear processes.
It must be realized that the pharmacokinetic models presented here are not 
concrete entities but abstractions which nevertheless are of great help in drug 
design and drug therapy.
ACKNOW LEDGM ENTS
The author is indebted to  Dr. A. H. Tomey of the Mathematic Service Department for 
assistance in the calculations and to Miss Coby Hurkmans for her unfailing assistance with 
compilation of the literature and correction of the text. The figures were made by the Medical 
Illustration Department of the Medical School.
REFERENCES
1. G. Aghajanian and O. H. L. Bing, C/in. Pharmacol. Ther. 5,611-614 (1964).
2. B. E. Ballard, Med. Biol. Eng. 4,483-490 (1966).
3. B. E. Ballard, J. Pharm. Sci. 57, 357-378 (1968).
4. A. H. Beckett and M. Rowland, J. Pharm. Pharmacol. 17, 59-69 (1965).
5. A. H. Beckett and M. Rowland, J. Pharm. Pharmacol. 17, 628-639 (1965).
6 . A. H. Beckett and M. Rowland, J. Pharm. Pharmacol. 17, Suppl., 109S-114S (1965).
7. A. H. Beckett, J. A. Salmon, and M. Mitchard, J. Pharm. Pharmacol. 21, 251-258 
(1969.)
8. N . Bergamini and G. Fowst, Arzneim.-Forsch. 15, 953-1002 (1965).
9. P. D. Berk, R. B. Howe, J. R. Bloomer, and N. I. Berlin, J. Clin. Invest. 48,2176-2188 
(1969).
10. B. A. Berkowitz, J. H. Asling, S. M. Shnider, and E. Leong Way, Clin. Pharmacol. 
Ther. 10, 320-328 (1969).
518 J. M. VAN ROSSUM
11. M. Berman and R. Schoenfeld, J. Appl. Phys. 27, 1361-1370(1956).
12. G. E. Boxer, V. C. Jelinek, R. Tompsett, R. Dubois, and A. O. Edison, J. Pharmacol. 
Exp. Ther. 92, 226-235 (1948).
13. H. D. Brainerd, H. B. Bruyn, G. Meiklejohn, and L. O’Gara, Antibiot. Chemother. 
( Washington, D.C.) 1, 447-160 (1951).
14. B. B. Brodie and J. Axelrod, J. Pharmacol. Exp. Ther. 98, 97-104 (1950).
15. B. B. Brodie, J. J. Bums, L. C. Mark, P. A. Lief, E. Bemstein, and E. M. Papper, 
J. Pharmacol. Exp. Ther. 109, 26-34 (1953).
16. P. Bünger, W. Diller, J. Führ, and E. Kriiger-Thiemer, Arzneim. Forsch. 11, 247-256 
(1961).
17. J. 1. Bums, A m . N. Y. Acctd. Sci. 151, 959-967 (1968).
18. J. J. Bums, T. F. Yü, P. G. Dayton, A. B. Gutman, and B. B. Brodie, A m . N. Y. Acad. 
Sci. 86, 253-262 (1960).
19. E. Bütikofer, P. Cottier, P. Imhof, H. Keberle, W. Riess, and K . Schmid, Naunyn- 
Schmiedebergs Arch. Exp. Pathol. Pharmakol. 244, 97-108 (1962).
20. Computer Programs, “Nonlinear Leastsquares Regression Subroutine of the B.M.D. 
X85 Series.”  I.B .M .; D. W. Marquardt, DPE-NLIN, Share General Library Program 
No. 7-1354.
21. A. R. Cooke, D. D. Harrison, and A. P. Skyring, Amer. J. Dig. Dis. [N. S.] 8,244-250 
(1963).
22. R. E. Cutler and B. Orme, J. Amer. Med. Ass. 209,539-542 (1969).
23. J. A. F. de Silva, B. A. Koechlin, and G. Bader, J. Pharm. Sci. 55, 692-702 (1966).
24. L. Dettli, Arzneim.-Forsch. 13, 151-155 (1963).
25. L. Dettli, Arzneim.-Forsch. 13, 509-513 (1963).
26. W. Diller, Antibiot. Chemother. (Basel) 12, 85-94 (1964).
27. J. E. Doherty, W. J. Flanigan, and W. H. Perkins, Circulation 37, 865-869 (1968).
28. J. T. Doluisio and L. W. Dittert, Clin. Pharmacol. Ther. 10, 690-701 (1969).
29. J. T. Doluisio and J. V. Swintosky, Amer. J. Pharm. 137, 144-168 (1965).
30. J. T. Doluisio and J. V. Swintosky, Amer. J. Pharm, 137,175-193 (1965).
31. R. Dominguez, Med. Phys. 2, 476-489 (1950).
32. F. H. Dost, “Der Blutspiegel; Kinetik der Konzentrationsabtëufe in der Kreislauf- 
flüssigkeit.” Thieme, Leipzig, 1953.
33. F. H. Dost, Deut. Med. Wochenschr. 92, 264-268 (1967).
34. F. H. Dost, “Grundlagen der Pharmakokinetik.” Thieme, Stuttgart, 1968.
35. F. H. Dost and E. Gladtke, Arzneim.-Forsch. 17, 772-774 (1967).
36. H. Eagle, E. V. Newman, R. Greif, T. M. Burkholder, and S. Goodman, J. Clin. Invest. 
26, 919-928 (1947).
37. L. Engstedt, S. Johansson, and A. Nyberg, J. Lab. Clin. Med. 70, 195-203 (1967).
38. J. W. Estes, E. W. Pelikan, and E. Krüger-Thiemer, Clin. Pharmacol. Ther. 10, 329-336 
(1969).
39. M. Gibaldi, Amer. J. Pharm. Educ. 32, 929-937 (1968).
40. M. Gibaldi, J. Pharm. Sci. 58, 327-331 (1969).
41. M. Gibaldi, J. Pharm. Sci. 58,1133-1135 (1969).
42. J. Gorski, D. Toft, G. Shyamala, D. Smith, and A. Notides, Recent Progr. Horm. Res. 
24, 45-80(1968).
43. F. L. Grab and J. A. Reinstein, J. Pharm. Sci. 57, 1703-1706 (1968).
44. W. Hammer, C. M. Ideström and F. Sjöqvist, Antidepressant Drugs, Proc. Int. Symp., 
Ist, 1966 pp. 301-310(1967).
45. N. G. Heatley, Antibiot. Med. Clin. Ther. 11, 33-41 (1956).
7 . PHARMACOKINETICS 519
46. K. R. Heimlich, D . R. Macdonnel, T. L. Flanagan, and P. D. O’Brien, J. Pharm. Sci. 
50, 232-237 (1961).
47. H. Held and H. F . von Oldershausen, Klin. Wochenschr. 41, 78-80 (1969).
48. W. Heptner, O. Christ, H . M. Kellner, and W. Rupp, Acta Diabet. Lat. 6, Suppl. 1, 
105-115 (1969).
49. G. Hitzenberger and K. H. Spitzy, Arzneim.-Forsch. 7, 291-292 (1957).
50. L. E. Hollister and G. Levy, Chemotherapy 9,20-24 (1964).
51. F. M. Kamienny, M. Barr, and J. B. Nagwekar, J. Pharm. Sci. 58, 1318-1324 (1969).
52. E. Krüger-Thiemer, J. Theor. Biol. 13,212-235 (1966).
53. E. Krüger-Thiemer, in “Animal and Clinical Pharmacologic Techniques in  D rug 
Evaluation” (P. E. Siegler and J. H . Moyer, eds.), Vol. 2, pp. 217-238. Vear Book 
Publ., Chicago, Illinois, 1967.
54. E. Krüger-Thiemer, W. Diller, L. Dettli, P. Bünger, and J. Seydel, Antibiot. Chemother. 
(Basel) 12, 171-193 (1964).
55. E. Krüger-Thiemer, E. Wempe, and M. Töpfer, Arzneim.-Forsch. 15,1309-1317 (1965).
56. C. M. Kunin, Clin. Pharmacol. Tker. 7,166-179 (1966).
56a. J. M. J. Lamers, unpublished data (1969).
57. G. Levy, J. Pharm. Sci. 56, 1687-1688 (1967).
58. G . Levy, M. Gibaldi, and W. J. Jusko, J. Pharm. Sci. 58,422-424 (1969).
59. P. J. Lewi, A. E. F. Chandler, D. G. van Riel, P. J. Somers, F. T. N. Allewijn, J. G. H. 
Dony, and P. A. J. Janssen, Arzneim.-Forsch. 20, 684-693 (1970).
60. J. C. K. Loo and S. Riegelman, J. Pharm. Sci. 57, 918-928 (1968).
61. J. C. K. Loo and S. Riegelman, J. Pharm. Sci. 59, 53-56 (1970).
62. D . S. Lukas and R. E. Peterson, J. Clin. Invest. 45, 782-795 (1966).
63. A. R. Maass, B. Jenkins, Y. Shen, and P. Tannenbaum, Clin. Pharmacol. Ther. 10, 
366-371 (1969).
64. E. W. McChesney, M. J. Fasco, and W. F. Banks, Jr., J. Pharmacol. Exp. Ther. 158, 
323-331 (1967).
65. M. Mahfouz, Brit. J. Pharmacol. 4,295-303 (1949).
66 . W. W. Mapleson, J. Appl. Physiol. 18, 197-205 (1963).
67. J. Melholm-Hansen, M. Kristensen, L. Skovsted, and L. Korsgaard Christensen, 
Lancet 1 ,265-266 (1966).
68 . K. Münzel, Deut. Apoth.-Ztg. 107, 1261-1264, 1312-1315, 1359-1366, and 1473-1480 
(1967).
69. R. Nagashima and G. Levy, J. Pharm. Sci. 58, 845-849 (1969).
70. P. Naumann, Int. J. Clin. Pharmacol., Ther. Toxicol. 2, 113-115 (1967).
71. E. Nelson, J. Pharm. Sci. 50,181-192 (1961).
72. E. Nelson and T. Morioka, J. Pharm. Sci. 52, 864-868 (1963).
73. G. T. Okita, P. J. Talso, J. H. Curry, Jr., F . D. Smith, Jr., and E. M. K. Geiling, 
J. Pharmacol. Exp. Ther. 113, 376-382 (1965).
74. M. E. Plaut, C. J. O ’ConnelI, R. C. Pabico, and D. Davidson, J. Lab. Clin. Meel. 74, 
12-18 (1969).
75. H. Polster, Z . Kinderheilk. 79, 555-562 (1957).
76. L. F. Prescott, M. Sansur, W. Levin, and A. H. Conney, Clin. Pharnuicol. Ther. 9, 
605-615 (1968).
77. A. Ravn-Jonsen, M. Lunding, and O. Secher, Acta Pharmacol. Toxicol. 27, 193-201
(1969).
78. A. Rescigno and G. Segre, “ Drug and Tracer Kinetics." Ginn (Blaisdell), Baston, 
Massachusetts, 1966.
520 J. M. VAN ROSSUM
79. F. Reubi and C. Münger, Pharmacol. Clin. 1, 8-18 (1968).
80. F. Reubi and C. Vorburger, Klin. Wochenschr. 48,43-50 (1970).
81. S. Riegelman, Drug Inform. Buil. 3, 59-67 (1969).
82. S. Riegelman, J. C. K. Loo, and M. Rowland, J. Pharm. Sci. 57, 117-123 (1968).
83. S. Riegelman, J. C. K. Loo, and M. R ow land,/. Pharm. Sci. 57,128-133 (1968).
84. D. S. Riggs, “ Mathematical Approach to Physiological Problems.” Williams & Wilkins, 
Baltimore, Maryland, 1963.
85. K. Rommel, E. Gladtke, G. Mahr, K. Grimmel and H. Burkhardt, Schweiz. Med. 
Wochenschr. 98,1854-1859 (1968).
86. M. Rowland, J. Pharm. Sci. 58,508-509 (1969).
87. M. Rowland, L. Z. Benet, and S. Riegelman, J. Pharm. Sci. 59, 364-368 (1970).
88. M. Rowland. S. Riegelman, and W. L. Epstein, J. Pharm. Sci. 57,984-989 (1968).
89. M. Rowland, S. Riegelman, P. A. Harris, S. D. Sholkoff, and E. J. Eyring, Nature 
(London) 215, 413-414 (1967).
90. D . B. Scott, P. J. Jebson, C. W. Yellani, and D. G. Julian, Lancet 2,1209-1210 (1968).
91. C. W. Sheppard, / .  Appl. Phys. 19,70-76 (1948).
92. M. B. Siegert, F . W. Alsleben, W. Liebenschütz, and H. Remmer, Naunyn-Schmiede- 
bergs Arch. Exp. Pathol. Pharmakol. 247, 509-521 (1964).
93. D . L. Smith, T. J. Vecchio, and A. A. Forist, Metab., Clin. Exp. 14, 229-240 (1965).
94. G. H. Spray and L. J. Witts, Clin. Sci. 11, 273-281 (1952).
95. J. M. Stowers, L. W. Constable, and R. B. Hunter, Ann. N. Y. Acad. Sci. 74, 689-695 
(1959).
96. T. Teorell, Arch. Int. Pharmacodyn. Ther. 57, 205-225 (1937).
97. T. Teorell, Arch. Int. Pharmacodyn. Ther. 57, 226-240 (1937).
98. J. H. Thurston, H. S. Liang, J. S. Smith, and E. J. Valentini, J. Lab. Clin. Med. 72, 
699-704 (1968).
99. F. E. van Dam, Thesis, University of Nijmegen, Thoben-Offset, Nijmegen, The 
Netherlands (1968).
100. E. van der Kleijn, Arch. Int. Pharmacodyn. Ther. 178,193-215 (1969).
100a. C. A. M. van Ginneken, unpublished data (1970).
101. J. M. van Rossum, J. Pharm. Sci. 57, 2162-2165 (1968).
102. J. M. van Rossum and A. H. M. Tomey, J. Pharm. Pharmacol. 20, 390-393 (1968).
103. J. M. van Rossum and A. H. M. Tómey, Arch. Int. Pharmacodyn. 188, 200-203 (1970).
104. J. M. van Rossum and T. B. Vree, Ned. Tydschr. Geneesk. 113, 1944-1959 (1969).
105. S. Vedsö, Acta Pharmacol. Toxicol. 18, 157-164 (1961).
106. E. S. Vesell and J. G. Page, J. Clin. Invest. 48,2202-2209(1969).
107. J. von Rieder, Arzneim.-Forsch. 13, 81-103 (1963).
108. T. B. Vree, Ph.D. Thesis (1971) (in preparation).
109. T. B. Vree, A. T. J. M. Muskens, and J. M. van Rossum, J. Pharm. Pharmacol. 21, 
774-775 (1969).
110. T. B. Vree and J. M. van Rossum, Eur. J. Pharmacol. 7,227-230 (1969)
111. T. B. Vree and J. M. van Rossum, in “International Symposium on Amphetamines 
and Related Compounds” (E. C ostaand S. Garattini, eds.), pp. 165-190. Raven Press, 
New York, 1970.
112. T. B. Vree and J. 'M. van Rossum, Arch. Int. Pharmacodyn. (1971) (submitted for 
publication).
113. J. G. Wagner, J. Pharm. Sci. 50, 359-587 (1961).
114. J. G. Wagner, J. Pharm. Sci. 56, 489 494(1967).
115. J. G. Wagner, Clin. Pharmacol. Ther. 8,201-218 (1967).
116. J. G. Wagner, J. Clin. Pharmacol. New Drugs 7, 84-88 (1967).
7. PHARMACOKINETICS 521
117. J. G . Wagner, Anti. Rev. Pharmacol. 8 , 67-94 (1968).
118. J. G . Wagner, Drug. Intel. 3 ,82-87 (1969).
119. J .G . Wagner, Drug Intel. 4,250-257 (1969).
120. J. G. Wagner, L. G. Lesley, and R. S. Gove, Int. J. Clin. Pharmacol. Ther. Toxicol. 2, 
44-51 (1969).
121. J. G. Wagner and C. M. Metzler, J. Pharm. Sci. 56, 658-659(1967).
122. J. G. Wagner and C. M. Metzler, J. Pharm. Sci. 58, 87-92 (1969).
123. J. G . Wagner and E. Nelson, J. Pharm. Sci. 53, 1392-1403 (1964).
124. J. G. Wagner, J. I. Northam, C. D. Alway, and O. S. Carpenter, Nature (.London) 207, 
1301-1302 (1965).
125. J. G. Wagner, J. I. Northam, and W. T. Sokolski, Nature (London) 207,201-202 (1965). 
126 J. G . Wagner, E. Novak, L. G . Leslie, and C. M. Metzler, Int. J. Clin. Pharmacol.
Ther. Toxicol. 1, 261-285 (1968).
127. A. M. Walter and L. Heilmeyer, “Antibiotika Fibel, Antibiotika und Chemotherapie.” 
Thieme, Stuttgart, 1965.
128. C. F . Weiss, A. J. Glazko, and J. K. Weston, N. Engl. J. Med. 262,787-795 (1960).
129. P. Weiss, R. M. Hersey, C. A. Dujovne, and J. R. Bianchini, Clin. Pharmacol. Ther.
10, 401-406 (1969).
130. H . M. Wichmann, Inaugural-Dissertation, Justus Liebig-Universitat, Gieszen, D .B . R. 
(1967).
131. R . G. W iegandandP. G. Sanders,/. Pharmacol. Exp. Ther. 146, 271-275 (1964).
132. W. Wilbrandt, Schweiz. Med. Wochenschr. 94, 737-745 (1964).
133. G. R. Wilkinson and A. H. Beckett, J. Pharmacol. Exp. Ther. 162, 139-147 (1968).
134. T. D. Yih, “Report on Physico-chemical Properties of Some Barbiturates” (1970).
